Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 769 to 777 of 777 entries
Sorted by: Best Match Show Resources per page
Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study.

Diabetes care

Brüne M, Linnenkamp U, Andrich S, Jaffan-Kolb L, Claessen H, Dintsios CM, Schmitz-Losem I, Kruse J, Chernyak N, Hiligsmann M, Hermanns N, Icks A.
PMID: 33318124
Diabetes Care. 2021 Feb;44(2):407-415. doi: 10.2337/dc19-2487. Epub 2020 Dec 14.

OBJECTIVE: Increased health care use and costs have been reported in individuals with diabetes with comorbid depression. Knowledge regarding cost differences between individuals with diabetes alone and those with diabetes and diagnosed/undiagnosed depression is, however, scarce. We therefore compared...

Cite
Brüne M, Linnenkamp U, Andrich S, et al. Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. Diabetes Care. 2020;44(2):407-415doi: 10.2337/dc19-2487.
Brüne, M., Linnenkamp, U., Andrich, S., Jaffan-Kolb, L., Claessen, H., Dintsios, C. M., Schmitz-Losem, I., Kruse, J., Chernyak, N., Hiligsmann, M., Hermanns, N., & Icks, A. (2021). Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. Diabetes care, 44(2), 407-415. https://doi.org/10.2337/dc19-2487
Brüne, Manuela, et al. "Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study." Diabetes care vol. 44,2 (2021): 407-415. doi: https://doi.org/10.2337/dc19-2487
Brüne M, Linnenkamp U, Andrich S, Jaffan-Kolb L, Claessen H, Dintsios CM, Schmitz-Losem I, Kruse J, Chernyak N, Hiligsmann M, Hermanns N, Icks A. Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. Diabetes Care. 2021 Feb;44(2):407-415. doi: 10.2337/dc19-2487. Epub 2020 Dec 14. PMID: 33318124.
Copy Download .nbib Format: NLM
High cost of cancer treatment doesn't reflect benefits, say specialists.

BMJ (Clinical research ed.)

Hawkes N.
PMID: 21952509
BMJ. 2011 Sep 27;343:d6220. doi: 10.1136/bmj.d6220.

No abstract available.

Cite
Hawkes N. High cost of cancer treatment doesn't reflect benefits, say specialists. BMJ. 2011;343:d6220doi: 10.1136/bmj.d6220.
Hawkes, N. (2011). High cost of cancer treatment doesn't reflect benefits, say specialists. BMJ (Clinical research ed.), 343d6220. https://doi.org/10.1136/bmj.d6220
Hawkes, Nigel. "High cost of cancer treatment doesn't reflect benefits, say specialists." BMJ (Clinical research ed.) vol. 343 (2011): d6220. doi: https://doi.org/10.1136/bmj.d6220
Hawkes N. High cost of cancer treatment doesn't reflect benefits, say specialists. BMJ. 2011 Sep 27;343:d6220. doi: 10.1136/bmj.d6220. PMID: 21952509.
Copy Download .nbib Format: NLM
Challenges related to palliative care.

The Lancet. Oncology

Kaasa S, Payne S, Sjøgren P.
PMID: 21958498
Lancet Oncol. 2011 Sep;12(10):925-7. doi: 10.1016/S1470-2045(11)70226-1.

No abstract available.

Cite
Kaasa S, Payne S, Sjøgren P. Challenges related to palliative care. Lancet Oncol. 2011;12(10):925-7doi: 10.1016/S1470-2045(11)70226-1.
Kaasa, S., Payne, S., & Sjøgren, P. (2011). Challenges related to palliative care. The Lancet. Oncology, 12(10), 925-7. https://doi.org/10.1016/S1470-2045(11)70226-1
Kaasa, Stein, et al. "Challenges related to palliative care." The Lancet. Oncology vol. 12,10 (2011): 925-7. doi: https://doi.org/10.1016/S1470-2045(11)70226-1
Kaasa S, Payne S, Sjøgren P. Challenges related to palliative care. Lancet Oncol. 2011 Sep;12(10):925-7. doi: 10.1016/S1470-2045(11)70226-1. PMID: 21958498.
Copy Download .nbib Format: NLM
The opportunity cost of cancer care: a statement from NICE.

The Lancet. Oncology

Rawlins MD, Chalkidou K.
PMID: 21958502
Lancet Oncol. 2011 Sep;12(10):931-2. doi: 10.1016/S1470-2045(11)70218-2.

No abstract available.

Cite
Rawlins MD, Chalkidou K. The opportunity cost of cancer care: a statement from NICE. Lancet Oncol. 2011;12(10):931-2doi: 10.1016/S1470-2045(11)70218-2.
Rawlins, M. D., & Chalkidou, K. (2011). The opportunity cost of cancer care: a statement from NICE. The Lancet. Oncology, 12(10), 931-2. https://doi.org/10.1016/S1470-2045(11)70218-2
Rawlins, Michael D, and Chalkidou, Kalipso. "The opportunity cost of cancer care: a statement from NICE." The Lancet. Oncology vol. 12,10 (2011): 931-2. doi: https://doi.org/10.1016/S1470-2045(11)70218-2
Rawlins MD, Chalkidou K. The opportunity cost of cancer care: a statement from NICE. Lancet Oncol. 2011 Sep;12(10):931-2. doi: 10.1016/S1470-2045(11)70218-2. PMID: 21958502.
Copy Download .nbib Format: NLM
Goals, targets, and tactics: making health care policy decisions explicit.

Journal of health politics, policy and law

Dudley RA, Luft HS.
PMID: 10503154
J Health Polit Policy Law. 1999 Aug;24(4):705-13. doi: 10.1215/03616878-24-4-705.

No abstract available.

Cite
Dudley RA, Luft HS. Goals, targets, and tactics: making health care policy decisions explicit. J Health Polit Policy Law. 1999;24(4):705-13doi: 10.1215/03616878-24-4-705.
Dudley, R. A., & Luft, H. S. (1999). Goals, targets, and tactics: making health care policy decisions explicit. Journal of health politics, policy and law, 24(4), 705-13. https://doi.org/10.1215/03616878-24-4-705
Dudley, R A, and Luft, H S. "Goals, targets, and tactics: making health care policy decisions explicit." Journal of health politics, policy and law vol. 24,4 (1999): 705-13. doi: https://doi.org/10.1215/03616878-24-4-705
Dudley RA, Luft HS. Goals, targets, and tactics: making health care policy decisions explicit. J Health Polit Policy Law. 1999 Aug;24(4):705-13. doi: 10.1215/03616878-24-4-705. PMID: 10503154.
Copy Download .nbib Format: NLM
Private Equity In Dermatology: Effect On Price, Utilization, And Spending.

Health affairs (Project Hope)

Braun RT, Bond AM, Qian Y, Zhang M, Casalino LP.
PMID: 33939519
Health Aff (Millwood). 2021 May;40(5):727-735. doi: 10.1377/hlthaff.2020.02062.

Private equity firms have increasingly acquired physician practices, and particularly dermatology practices. Analyzing commercial claims from the Health Care Cost Institute (2012-17), we used a difference-in-differences design within an event study framework to estimate the prevalence of private equity...

Cite
Braun RT, Bond AM, Qian Y, et al. Private Equity In Dermatology: Effect On Price, Utilization, And Spending. Health Aff (Millwood). 2021;40(5):727-735doi: 10.1377/hlthaff.2020.02062.
Braun, R. T., Bond, A. M., Qian, Y., Zhang, M., & Casalino, L. P. (2021). Private Equity In Dermatology: Effect On Price, Utilization, And Spending. Health affairs (Project Hope), 40(5), 727-735. https://doi.org/10.1377/hlthaff.2020.02062
Braun, Robert Tyler, et al. "Private Equity In Dermatology: Effect On Price, Utilization, And Spending." Health affairs (Project Hope) vol. 40,5 (2021): 727-735. doi: https://doi.org/10.1377/hlthaff.2020.02062
Braun RT, Bond AM, Qian Y, Zhang M, Casalino LP. Private Equity In Dermatology: Effect On Price, Utilization, And Spending. Health Aff (Millwood). 2021 May;40(5):727-735. doi: 10.1377/hlthaff.2020.02062. PMID: 33939519.
Copy Download .nbib Format: NLM
Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population.

Current medical research and opinion

Tkacz JP, Rance K, Waddell D, Aagren M, Hammerby E.
PMID: 33754932
Curr Med Res Opin. 2021 Jun;37(6):957-965. doi: 10.1080/03007995.2021.1903848. Epub 2021 Apr 02.

OBJECTIVE: To assess total and allergic rhinitis (AR)-related healthcare costs among AR patients residing in the United States with a focus on patients persisting with AIT.METHODS: AR patients were identified in the IBM MarketScan database between 1 January 2014...

Cite
Tkacz JP, Rance K, Waddell D, et al. Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Curr Med Res Opin. 2021;37(6):957-965doi: 10.1080/03007995.2021.1903848.
Tkacz, J. P., Rance, K., Waddell, D., Aagren, M., & Hammerby, E. (2021). Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Current medical research and opinion, 37(6), 957-965. https://doi.org/10.1080/03007995.2021.1903848
Tkacz, Joseph P, et al. "Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population." Current medical research and opinion vol. 37,6 (2021): 957-965. doi: https://doi.org/10.1080/03007995.2021.1903848
Tkacz JP, Rance K, Waddell D, Aagren M, Hammerby E. Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. Curr Med Res Opin. 2021 Jun;37(6):957-965. doi: 10.1080/03007995.2021.1903848. Epub 2021 Apr 02. PMID: 33754932.
Copy Download .nbib Format: NLM
The rising cost of medical education and its significance for (not only) psychiatry.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry

Verduin ML, Balon R, Coverdale JH, Louie AK, Beresin EV, Roberts LW.
PMID: 24752697
Acad Psychiatry. 2014 Jun;38(3):305-8. doi: 10.1007/s40596-014-0118-7. Epub 2014 Apr 22.

No abstract available.

Cite
Verduin ML, Balon R, Coverdale JH, et al. The rising cost of medical education and its significance for (not only) psychiatry. Acad Psychiatry. 2014;38(3):305-8doi: 10.1007/s40596-014-0118-7.
Verduin, M. L., Balon, R., Coverdale, J. H., Louie, A. K., Beresin, E. V., & Roberts, L. W. (2014). The rising cost of medical education and its significance for (not only) psychiatry. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry, 38(3), 305-8. https://doi.org/10.1007/s40596-014-0118-7
Verduin, Marcia L, et al. "The rising cost of medical education and its significance for (not only) psychiatry." Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry vol. 38,3 (2014): 305-8. doi: https://doi.org/10.1007/s40596-014-0118-7
Verduin ML, Balon R, Coverdale JH, Louie AK, Beresin EV, Roberts LW. The rising cost of medical education and its significance for (not only) psychiatry. Acad Psychiatry. 2014 Jun;38(3):305-8. doi: 10.1007/s40596-014-0118-7. Epub 2014 Apr 22. PMID: 24752697.
Copy Download .nbib Format: NLM
Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe.

BMC public health

Divajeva D, Marsh T, Logstrup S, Kestens M, Vemer P, Kriaucioniene V, Peresson S, O'Kelly S, Rito A, Webber L.
PMID: 24886110
BMC Public Health. 2014 May 16;14:456. doi: 10.1186/1471-2458-14-456.

BACKGROUND: The majority of chronic disease is caused by risk factors which are mostly preventable. Effective interventions to reduce these risks are known and proven to be applicable to a variety of settings. Chronic disease is generally developed long...

Cite
Divajeva D, Marsh T, Logstrup S, et al. Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe. BMC Public Health. 2014;14:456doi: 10.1186/1471-2458-14-456.
Divajeva, D., Marsh, T., Logstrup, S., Kestens, M., Vemer, P., Kriaucioniene, V., Peresson, S., O'Kelly, S., Rito, A., & Webber, L. (2014). Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe. BMC public health, 14456. https://doi.org/10.1186/1471-2458-14-456
Divajeva, Diana, et al. "Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe." BMC public health vol. 14 (2014): 456. doi: https://doi.org/10.1186/1471-2458-14-456
Divajeva D, Marsh T, Logstrup S, Kestens M, Vemer P, Kriaucioniene V, Peresson S, O'Kelly S, Rito A, Webber L. Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe. BMC Public Health. 2014 May 16;14:456. doi: 10.1186/1471-2458-14-456. PMID: 24886110; PMCID: PMC4047783.
Copy Download .nbib Format: NLM
Showing 769 to 777 of 777 entries